INTRODUCTION
============

Leishmaniasis is a neglected disease distributed in more than 98 countries in the world and it has been reported that almost 0.7--1.2 million cases of cutaneous leishmaniasis (CL) occur each year \[[@b1-kjp-57-1-1],[@b2-kjp-57-1-1]\]. Two common forms of CL, such as anthroponotic cutaneous leishmaniasis (ACL) caused by *Leishmania tropica* (*L. tropica*) and zoonotic CL (ZCL) caused by *L. major*, are present in Iran \[[@b3-kjp-57-1-1]--[@b6-kjp-57-1-1]\].

The clinical manifestations of leishmaniasis are of various form of a self-limiting lesion to damaging mucocutaneous lesions, which depend on the *Leishmanias* species and the type of immune response to the disease \[[@b7-kjp-57-1-1]\]. Antimonial drugs (SbV) are considered as the first line of drugs for all forms of *Leishmania* treatment \[[@b8-kjp-57-1-1]\]. However, their efficacy is decreased depending on the *Leishmanias* species and geographical regions \[[@b9-kjp-57-1-1]\].

Additionally, all current treatments have limitations derived from their high cost, route of administration, drug resistance, long duration of treatment and especially, serious side effects such as nephrotoxicity, hypokalemia, hepatic and pancreatic toxicity, hypotension and dysglycemia among others. Therefore, there is an urgent need for the development of innovative treatment modalities against leishmaniasis that are safe, inexpensive and easily available to the patients. Furthermore, the discovery of new lead compounds for this disease is a pressing concern for global health programs.

Selenium (Se) is an essential element for human health including antiviral activities, cancer prevention, antioxidant and anti-inflammatory effects \[[@b10-kjp-57-1-1]\]. Selenium ions ameliorate the immune response of hosts against various species of viral antigen and bacteria \[[@b11-kjp-57-1-1]\]. Several studies have demonstrated appropriate efficacy of selenium nanoparticles against *L. major, L. tropica,* and *L. infantum* \[[@b12-kjp-57-1-1]--[@b14-kjp-57-1-1]\].

Vesicular drug delivery is one of the approaches that encapsulate drug. Examples include niosomes, transferosomes, liposomes, provesicles and pharmacosomes. The benefits of niosomes and liposomes over other conventional forms are their action as a drug reservoir owing to their particulate nature. Niosomes have more stable structures than liposomes even in the emulsified form \[[@b15-kjp-57-1-1]\].

Niosomes are drug carriers with a bilayer structure in an aqueous phase which are formed by nonionic surfactants and cholesterol. They exhibit high stability, long shelf life and facilitate the delivery of drug at target site in a sustained mode. In addition, as a novel carrier of drugs, they are biocompatible, biodegradable and nonimmunogenic \[[@b16-kjp-57-1-1]\].

In this study, the niosomal formulation of selenium and in combination with glucantime were prepared and their activity was assessed using in vitro MTT assay, intra-macrophage model, and gene expression profile. The size and morphology of niosomal formulation were characterized. The aim of this study was to improve the penetration and effectivity of selenium and glucantime coupled with niosomes and compared with these drugs alone by in vitro susceptibility assays.

MATERIALS AND METHODS
=====================

Preparation of drug
-------------------

Glucantime (Sanofi-Aventis, Paris, France) and selenium dioxide 99.9% (SIGMA-ALDRICH/Lot 079K368021) were purchased from commercial sources in Iran. Glucantime and selenium were diluted in Roswell Park Memorial Institute medium (RPMI-1640) (Biosera, Nuaille, France) to prepare serial dilutions (12.5, 25, 50, 100, and 200 μg/ml) \[[@b17-kjp-57-1-1]\] freshly before performing each test.

For combination of glucantime and selenium, first and foremost, the concentrations of selenium remained constant, while glucantime was used in increasing order of concentrations (50, 100, and 200 μg/ml). Secondly, the concentrations of Glucantime were constant and selenium was decreasing in order of concentrations.

In the niosomal combination of glucantime and selenium, at first, the concentrations were based on selenium (selenium plus glucantime niosome) and thereafter, the serial dilutions were based on glucantime (glucantime plus selenium niosome).

Preparation of niosome
----------------------

Selenium niosome and selenium plus glucantime niosome were prepared using film hydration method \[[@b18-kjp-57-1-1]\]. In a round bottom flask, Span 40 (5 g/50 ml), Tween 40 (2.5 g/50 ml) and cholesterol (2.5 g/50 ml) were dissolved in chloroform. The chloroform was evaporated in a rotary evaporator at 60°C and 4 g for 30 min. The thin layer of film was left to cover the inner walls of the flask. The hydration of obtained film was performed by 5 ml deionized water, in which selenium (1%) and also combination of selenium (1%) and glucantime (1.5%) were dissolved at 55°C for 1 hr. The obtained niosomes were solicited for 30 min by bath sonication. To complete hydration, niosamal formulation of each drug were kept at room temperature (24±1°C) for 24 hr.

Characterization of niosomes
----------------------------

The size dispensation of the niosomes was determined using laser light diffraction method by Malvern apparatus (Malvern Mastersizer X, Malvern, UK). The morphology of niosomal formulations was surveyed using camera that was attached to a light microscope (Zeiss, Oberkochen, Germany), equipped with a computer controlled image analysis system.

*Leishmania* parasite culture
-----------------------------

*L. tropica* standard strain MHOM/IR/75/Mash2 was cultured in Novy-MacNeal-Nicolle (NNN) medium, incubated at 24°C±1 and subcultured in RPMI-1640 (Biosera) supplemented with 15% heat inactivated (at 56°C for 30 min) fetal bovine serum (FBS, Gibco, Carlsbad, California, USA), 1% penesterep (Life Technology, Carlsbad, California, USA).

Murine macrophage cell line culture
-----------------------------------

J774A.1 ATCC^®^ TIB-67^TM^ was purchased from the Pasteur Institute of Iran (Tehran, Iran) and cultured in DMEM medium supplemented with 10% inactivated FBS, 0.5% penicillin (Sigma, Poole, UK), 0.5% streptomycin (Sigma) and incubated at 37°C with 5% CO~2~.

Cytotoxicity of drugs on murine macrophage cells
------------------------------------------------

Prior to the tests on *L. tropica* extracellular promastigote and intracellular amastigote, the cytotoxicity concentrations of glucantime, selenium niosome, selenium plus glucantime, selenium plus glucantime niosome and glucantime plus selenium niosome were determined on J774 cells.

Murine macrophage cells (5×10^4^) were cultured in 96 well-microplate and incubated at 37°C with 5% CO~2~ for 2 hr. After the incubation period, different concentrations of each drug (12.5--200 μg/ml) were added to each well of the 96-wellmicroplate and incubated for 72 hr. Thereafter, 10 μl MTT (3-\[4, 5-Dimethylthiazol-2-yl\]-2, 5-diphenyltetrazolium bromide; Thiazolyl blue) (Sigma Aldrich, St. Louis, Missouri, USA) (5 mg/ml) was added to each well of the microplate and incubated for 3 hr. The wells with medium and parasite without any drugs were considered as untreated control. Thereafter, 100 μl Dimethyl sulfoxide (DMSO) (Merck, Darmstadt, Germany) were added for dissolving formazan crystals and incubated at room temperature in the dark for 1 hr. Optical density (OD) was read at 490 nm using ELISA-reader (Bio Tek-ELX800, Winooski, Vermont, USA). The 50% cytotoxicity concentration (CC~50~) was determined by probit test in SPSS software version 20 (SPSS Inc., Chicago, Illinois, USA).

Extra-cellular promastigote assay
---------------------------------

Promastigotes (1×10^5^) were cultured at log phase in 96-well microliter plate and 10 μl of different concentrations of all drugs with 60 μl RPMI-1640 were added to each well and incubated at 24°C±1 for 72 hr. Promastigote in medium without any drug was considered as the untreated control, while medium with no promastigote was used as blank. All experiments were performed 3 times. Ten μl of MTT solution in RPMI-1640 (no phenol red) was added to each well and incubated at 24±1°C for 4 hr. The reaction was terminated by DMSO and read using an ELISA reader at 490 nm. The 50% inhibitory concentration (IC~50~) was assessed by probit test using SPSS software.

Intra-cellular amastigote assay
-------------------------------

Cells (1×10^5^ cells) of the J774 murine macrophage cell line were cultured on the slides in sterile plates and incubated at 37°C, with 5% CO~2~ for 2 hr. The promastigotes (1×10^6^) in the stationary phase were added to each slide and then incubated for 24 hr. After the incubation period, different concentrations of all drugs were added to the slides and incubated at 37°C for 72 hr. At the end, the slides were dried, fixed with methanol, and stained by Giemsa for evaluation under a light microscope. The effectiveness of each drug was evaluated by the mean number of amastigotes in 100 macrophages. Every experiment was performed in triplicate.

Quantitative real-time PCR (qPCR)
---------------------------------

RNeasy^®^ mini kit (Qiagen, Chatsworth, California, USA) was used for the extraction of RNA according to the manufacturer's protocol. Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA) was used for the determination of quantity and purity of each sample. Then, cDNA was synthesized using the TaKaRa Prime Script^TM^ RT reagent kits (Takara Clontech, California, USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) \[[@b19-kjp-57-1-1],[@b20-kjp-57-1-1]\] was used as reference gene for gene expression of IL-12 and IL-10 in murine macrophage cells (J-774) and RPS18 Ribosomal protein (S18) \[[@b21-kjp-57-1-1],[@b22-kjp-57-1-1]\] for gene expression of metacaspase in *Leishmania* ([Table 1](#t1-kjp-57-1-1){ref-type="table"}). Quantitative RT-PCR of target cDNA was run on a Rotorgene 3000 cycler system (Corbett Research, Sydney, Australia). The PCR reaction for mRNA detection was carried out in reaction volumes (10 μl) including 5 μl 2X SYBR Green Supermix (SYBR^®^ Premix Ex Taq^TM^, Takara Clontech), 250 nmol forward and 250 nmol reverse primer, and 1 μl cDNA diluted in RNase-free water. PCR reactions were performed in duplicates and results were normalized to the levels of GAPDH and S18 genes as reference genes. To calculate the relative value of the expression level, 2^−ΔΔCt^ method was used as a relative quantification approach for qPCR data analysis.

Statistical analyses
--------------------

Data analysis was done using SPSS software version 20. ANOVA and independed *t*-test were used to determine the significant relationship between the treatment groups, also IC~50~ and CC~50~ were calculated by probit test. The mean 2^−ΔCt^ for treatment and the mean 2^−ΔCt^ for control for each cytokine were compared using GRAPHPAD PRISM 6 (GraphPad Software Inc., San Diego, California, USA). *P* \<0.05 was considered as significant.

The Minimum Standards of Reporting Checklist contains details of the experimental design, and statistics, and resources used in this study.

RESULTS
=======

Niosome preparation
-------------------

In the first step, 3 different formulations for each drug were prepared and then the determination of the morphology and size was carried out. Selection of the best formulation procedure due to medium spherical multi-layer vesicles ([Fig. 1](#f1-kjp-57-1-1){ref-type="fig"}) with sizes of 9.75±0.35 and 5.4±0.14 μm for selenium noisome and selenium plus glucantime niosome was accomplished, respectively.

Cytotoxicity analysis
---------------------

In the investigation of the cytotoxicity of drugs, various concentrations of these drugs and niosomal formulation of them (12.5--200 μg/ml) were applied on macrophage cell-line as harboring cells. The CC~50~ of each drug based on OD was assessed ([Table 2](#t2-kjp-57-1-1){ref-type="table"}).

Based on the cytotoxicity analysis, no toxic effect was observed in all drugs at concentrations of 12.5, 25, 50, 100, and 200 μg/ml and as such, the drugs were used in next steps.

Leishmanicidal effects on extra-cellular promastigotes
------------------------------------------------------

The inhibitory activity demonstrated a dose-dependent pattern ([Figs. 2](#f2-kjp-57-1-1){ref-type="fig"}, [3](#f3-kjp-57-1-1){ref-type="fig"}). All drugs inhibited the growth of promastigotes effectively; however, selenium plus glucantime niosome showed a higher inhibitory effect ([Fig. 2](#f2-kjp-57-1-1){ref-type="fig"}). The IC~50~ values of selenium and selenium niosome were 78.07±5 and 48.2±6.2 μg/ml, respectively. Also, the IC~50~ values of selenium plus glucantime niosome and glucantime plus selenium niosome were 16.11±0.99 and 42.17±2.47 μg/ml, respectively. All the drugs showed a good inhibition index against the growth rate of promastigotes, but selenium plus glucantime niosome formulation was the best (*P* \<0.05).

Leishmanicidal effects on intra-cellular amstigotes
---------------------------------------------------

The mean number of intracellular amastigotes in each macrophage, which were treated with drugs and niosomal formulation, was evaluated. Selenium and selenium niosome significantly decreased the mean number of amastigotes in each macrophage as compared with the glucantime or untreated control ([Table 3](#t3-kjp-57-1-1){ref-type="table"}). Various concentrations of combined niosomal formulation were able to significantly inhibit the number of intracellular amastigotes in macrophages as compared with the untreated control (*P* \<0.001) ([Table 3](#t3-kjp-57-1-1){ref-type="table"}).

As regard the effect of all drugs, selenium plus glucantime niosome was significantly more effective than selenium in simple or in combination with Glucantime ([Table 4](#t4-kjp-57-1-1){ref-type="table"}) and the IC~50~ of this formulation against amastigotes was 8.67 μg/ml (*P* \<0.001) ([Table 2](#t2-kjp-57-1-1){ref-type="table"}).

Real time
---------

The results of this study showed that the peak of IL-10, as a measure of Th-2, was significantly decreased (*P* \<0.001), although the levels of IL-12 and metacaspase were increased (*P* \<0.001) from concentration of 12.5 to 200 μg/ml ([Fig. 4](#f4-kjp-57-1-1){ref-type="fig"}).

DISCUSSION
==========

Antimonials are used as the first line of CL treatment due to their moderate side effects and painful injection \[[@b23-kjp-57-1-1]\]. So far, no effective topical drugs have been found to be useful in the treatment of CL, because intracellular parasites live in the macrophage in the deep layer of derm and as such, it is difficult to access the amastigotes \[[@b24-kjp-57-1-1]\].

Therefore, the use of novel delivering of drugs, which is controlled and targeted, is considered to be an effective approach. The application of niosomes and liposomes acting as drug delivery, would be loaded with different drugs. These delivering can control the release drug to the target sites and protect drug from degradation \[[@b25-kjp-57-1-1]\]. Niosomes, as compared with liposomes, are more stable chemically and have long half-life during storage \[[@b18-kjp-57-1-1]\].

However, small amounts of selenium are required for parasites such as *Leishmania* and *Trypanosoma* \[[@b26-kjp-57-1-1]\] but high concentration of this could be toxic and can cause biochemical and morphological changes such as DNA fragmentation in promastigotes form of *Leishmania*. One of the most important changes that occur in programmed cell death is DNA fragmentation \[[@b27-kjp-57-1-1]\].

In this study, selenium niosome, selenium plus glucantime niosome or glucantime plus selenium showed lower cytotoxicity as compared with selenium alone. This result is in agreement with other previous studies which reported that Se NPs demonstrated low toxicity \[[@b28-kjp-57-1-1],[@b29-kjp-57-1-1]\]. This result also showed that niosomal formulation had the least cytotoxicity because of its targeting delivery of drugs. Hence, we could evaluate the effects of these formulations on the 2 forms of *L. tropica* using in vitro methods.

Several studies reported that Se NPs had significant effects on *Leishmania* species \[[@b12-kjp-57-1-1],[@b13-kjp-57-1-1],[@b30-kjp-57-1-1],[@b31-kjp-57-1-1]\]. The results of the present study also showed the anti-leishmanial effects of niosomal formulation of selenium along with glucantime. The IC~50~ values indicated that selenium coupled with glucantime niosome were the most effective formulation against both extra- and intracellular stages of *L. tropica* with the highest safety index (SI=127) and inhibitory level. As regard the evaluation of SI, niosomal formulation was significantly more active against 2 forms of *L. tropica* rather than glucantime and selenium as simple forms.

Combination therapy is the best strategy to prevent drug resistance and also enhance efficacy rate against CL. Other advantages of combination therapy are reduction in the length of treatment, in the administration of doses, side effects and cost \[[@b32-kjp-57-1-1]\]. In this study, the niosomal combination of selenium plus glucantime was the most effective on *L. tropica*. Also, other studies have confirmed that combination therapies with meglumine antiminiate along with different drugs, such as terbinafine, imiquimod, allopurinol or verapamil could potentiate synergistic effects in the treatment of CL \[[@b33-kjp-57-1-1]--[@b35-kjp-57-1-1]\].

Th1 (Interferon-γ, tumor necrosis factor-α, IL-12, and nitric oxide) and Th2 (IL-4, IL-10, IL-13, and transforming growth factor-β) are 2 different immune response in *Leishmania* infection \[[@b36-kjp-57-1-1],[@b37-kjp-57-1-1]\]. In the present study, selenium plus glucantime niosome showed an immunomodulatory role for the inhibition of IL-10 and induction of IL-12, which is indicative of an immunomodulatory role of this formulation in cell death as another possible mechanism of action exerted by this combination. Previous studies have shown that the progression of diseases is correlated with IL-10 which played a potent immunosuppressive activity in leishmaniasis, such as suppression of macrophage activation \[[@b38-kjp-57-1-1]\]; the biological processes leading to cell death are multifactorial. Cell death process in protozoa, plants, and fungi is due to the expression of metacaspase as cysteine peptidases \[[@b39-kjp-57-1-1]\].

The metacaspase in *L. major* and *L. donovani* plays an important role in the programmed cell death pathways \[[@b39-kjp-57-1-1]--[@b42-kjp-57-1-1]\].

The results of the present study showed that metacaspase was increased in promastigote form of *L. tropica* treated with selenium plus glucantime niosome. Also, increasing the expression level of metacaspase gene contributed to apoptosis in this parasite, and these findings obtained during the study are in line with the results of previous study \[[@b41-kjp-57-1-1]\].

The results of the present study showed that selenium niosome possesses a powerful anti-leishmanial effect and enhanced potent lethal activity especially in combination with glucantime in niosomal form as evidenced by the in vitro experiments. Selenium plus glucantime niosome inhibited Th-2 cytokine, induced the Th-1 cytokine mediators and stimulated an immunomodulatory role against the different stages of *L. tropica*. Such progression of lethal action in in vitro model would be prerequisite for performing further investigation in clinical settings.

This project (protocol no. 94/691) was granted approval by the Leishmaniasis Research Center and received financial support from the Vice Chancellor for Research at the Kerman University of Medical Sciences. This study is a part of a PhD dissertation for pursuit of a Ph.D by Research degree in Leishmaniasis and skin diseases.

**CONFLICT OF INTEREST**

The authors have no conflicts of interest.

![Microscopic images of Span/Tween 40 (molar ratio=5:5) selenium niosome (A), and Span/Tween 40 (molar ratio=5:5) selenium plus glucantime niosome (B).](kjp-57-1-1f1){#f1-kjp-57-1-1}

![Comparison of inhibitory effect selenium, selenium niosome, selenium plus glucantime niosome and glucantime plus selenium niosome, on *Leishmania tropica* promastigotes with glucantime as a standard drug, by MTT assay (\**P*\<0.05).](kjp-57-1-1f2){#f2-kjp-57-1-1}

![Inhibitory effect of selenium plus glucantime on promastigotes of *Leishmania tropica*.](kjp-57-1-1f3){#f3-kjp-57-1-1}

![The gene expression profiles of (A) metacaspase, (B) IL-10, and (C) IL-12p40 on the *Leishmania tropica* treated by the selenium plus glucantime niosome and glucantime in comparison with untreated control (\**P*\<0.001) as measured by using real-time PCR.](kjp-57-1-1f4){#f4-kjp-57-1-1}

###### 

Primers which were used for real-time PCR

  Primers                         Gene                      Forward Sequence (5′-3′)   Reverse Sequence (5′-3′)       Product size (bp)
  ------------------------------- ------------------------- -------------------------- ------------------------------ -------------------
  Macrophages murine cells        IL-12 P40                 CTGGAGCACTCCCCATTCCTA      GCAGACATTCCCGCCTTTG            160
  IL-10                           CTTACTGACTGGCATGAGGATCA   GCAGCTCTAGGAGCATGTGC       101                            
  GAPDH                           AGCTTCGGCACATATTTCATCTG   CGTTCACTCCCATGACAAACA      89                             
                                                                                                                      
  Promastigotes of *L. tropica*   Metacaspase               CAGCAACAATTCCTGGCGATA      AAGTTTGAAGTAAAAGGAGACAATTTGG   140
  RPS18 Ribosomal protein (S18)   GTTGAGGTGCGTGGTCTGTC      TGCAGGTTGCTCAGGAGCTT       166                            

###### 

Comparison of the IC~50~ values of selenium, selenium niosome, glucantime, glucantime plus selenium niosome and selenium plus glucantime niosome on *Leishmania tropica* promastigotes and amastigotes, CC~50~ values of drugs on macrophage and SI index

  Drug                               Amastigote     Promastigote   Macrophage   SI                
  ---------------------------------- -------------- -------------- ------------ -------- -------- --------
  Glucantime                         222.31±28.04   ≤0.001         144.5±97.3   ≤0.001   1634     7.35
                                                                                                  
  Selenium                           216.18±2.82    ≤0.001         78.07±5      ≤0.001   260.51   1.2
                                                                                                  
  Selenium niosome                   78.45±1.3      ≤0.001         48.2±6.2     ≤0.001   1202     15.32
                                                                                                  
  Selenium plus glucantime niosome   8.67±0.1       ≤0.001         16.11±0.99   ≤0.001   1105     127.45
                                                                                                  
  Glucantime plus selenium niosome   14.47±2.22     ≤0.001         42.17±2.47   ≤0.001   1511     104.42

IC~50~, Concentration of drug that caused 50% of growth inhibition of promastigotes and amastigotes; CC~50~, Concentration of drug that caused 50% of cytotoxicity on macrophages; SI (Selectivity index), the ratio between CC~50~ on J774 cells and IC~50~ against *L. tropica* amastigotes (SI=CC~5O~/IC~50~≥10 non-toxic).

###### 

Comparison of the overall mean effect of various concentrations of selenium, selenium niosome and, glucantime, selenium plus glucantime niosome, and glucantime plus selenium niosome on the mean number of amastigotes in macrophage

  Concentration (μg/ml)   Glucantime   Selenium   Selenium niosome   Selenium plus glucantime niosome   Glucantime plus selenium niosome                                               
  ----------------------- ------------ ---------- ------------------ ---------------------------------- ---------------------------------- -------- ------------ -------- ------------ --------
  0 (Untreated control)   22±1         NR         22±0.1             NR                                 22±1                               NR       32±0.56      NR       32±0.56      NR
                                                                                                                                                                                       
  12.5                    21±0.26      0.51       14.7±0.1           ≤0.001                             15±0.2                             ≤0.001   13.95±0.13   ≤0.001   15.9±0.38    ≤0.001
                                                                                                                                                                                       
  25                      20±0.75      0.51       13.03±0.12         ≤0.001                             13±0.7                             ≤0.001   13±0.1       ≤0.001   13.84±0.63   ≤0.001
                                                                                                                                                                                       
  50                      15±0.17      ≤0.001     12.37±0.21         ≤0.001                             10±0.2                             ≤0.001   12.95±0.05   ≤0.001   12.85±0.27   ≤0.001
                                                                                                                                                                                       
  100                     12±0.26      ≤0.001     11.56±0.52         ≤0.001                             9±0.05                             ≤0.001   11.06±0.19   ≤0.001   10.83±0.35   ≤0.001
                                                                                                                                                                                       
  200                     10±0.62      ≤0.001     8.03±0.14          ≤0.001                             8±0.7                              ≤0.001   6.32±0.25    ≤0.001   6.45±0.14    ≤0.001

###### 

Comparison of the overall mean effect of various concentrations of selenium plus glucantime on the mean number of amastigotes in each macrophage

  Concentrations (μg/ml)   Glucantime plus selenium   
  ------------------------ -------------------------- --------
  0 (Untreated control)    36±0.38                    NR
  50+50                    20.4±0.4                   ≤0.001
  50+100                   19.76±0.45                 ≤0.001
  50+200                   18.01±0.4                  ≤0.001
  100+50                   19.7±0.3                   ≤0.001
  100+100                  17.2±0.37                  ≤0.001
  100+200                  13.7±0.46                  ≤0.001
  200+50                   17.07±0.31                 ≤0.001
  200+100                  16.2±0.41                  ≤0.001
  200+200                  13.67±0.5                  ≤0.001
